2-Oct-2026
Opko Health Triggers Conversion of 2029 Convertible Notes
TipRanks (Fri, 2-Oct 4:29 PM ET)
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
Globe Newswire (Tue, 8-Sep 1:55 PM ET)
Globe Newswire (Thu, 13-Aug 9:15 AM ET)
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
Globe Newswire (Mon, 3-Aug 7:00 AM ET)
OPKO Health Narrows Losses and Advances Pipeline in Q2 2026 Amid Key Program Milestones
Market Chameleon (Tue, 28-Jul 6:29 AM ET)
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
Globe Newswire (Mon, 27-Jul 4:05 PM ET)
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
Globe Newswire (Thu, 23-Jul 12:30 PM ET)
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Opko Health trades on the NASDAQ stock market under the symbol OPK.
As of October 2, 2026, OPK stock price declined to $1.56 with 1,346,982 million shares trading.
OPK has a beta of 0.68, meaning it tends to be less sensitive to market movements. OPK has a correlation of 0.04 to the broad based SPY ETF.
OPK has a market cap of $1.16 billion. This is considered a Small Cap stock.
Last quarter Opko Health reported $164 million in Revenue and -$.01 earnings per share. This beat revenue expectation by $32 million and exceeded earnings estimates by $.09.
In the last 3 years, OPK traded as high as $2.04 and as low as $.85.
The top ETF exchange traded funds that OPK belongs to (by Net Assets): IWM, VTI, VB, VXF, IWN.
OPK has underperformed the market in the last year with a price return of +1.3% while the SPY ETF gained +16.1%. OPK has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +2.6% and -6.6%, respectively, while the SPY returned +3.6% and +1.0%, respectively.
OPK support price is $1.53 and resistance is $1.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OPK shares will trade within this expected range on the day.